Efficacy and Safety of Insulin Aspart Biosimilar SAR341402 Versus Originator Insulin Aspart in People with Diabetes Treated for 26 Weeks with Multiple Daily Injections in Combination with Insulin Glargine: A Randomized Open-Label Trial (GEMELLI 1).
Saved in:
| Title: | Efficacy and Safety of Insulin Aspart Biosimilar SAR341402 Versus Originator Insulin Aspart in People with Diabetes Treated for 26 Weeks with Multiple Daily Injections in Combination with Insulin Glargine: A Randomized Open-Label Trial (GEMELLI 1). |
|---|---|
| Authors: | Garg SK; Barbara Davis Center for Diabetes, University of Colorado Anschutz Medical Campus, Aurora, Colorado., Wernicke-Panten K; Sanofi-Aventis Deutschland GmbH, Frankfurt, Germany., Wardecki M; Sanofi, Warszawa, Poland., Kramer D; Sanofi-Aventis Deutschland GmbH, Frankfurt, Germany., Delalande F; Ividata, Paris, France., Franek E; Mossakowski Clinical Research Centre, Polish Academy of Sciences, and CSK MSWiA, Warszawa, Poland., Sadeharju K; Terveystalo Seinäjoki, Seinäjoki, Finland., Monchamp T; Endocrinology Services Northwest, Bend, Oregon., Mukherjee B; Sanofi, Paris, France., Shah VN; Barbara Davis Center for Diabetes, University of Colorado Anschutz Medical Campus, Aurora, Colorado. |
| Source: | Diabetes technology & therapeutics [Diabetes Technol Ther] 2020 Feb; Vol. 22 (2), pp. 85-95. |
| Publication Type: | Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; Equivalence Trial |
| Journal Info: | Publisher: Mary Ann Liebert, Inc Country of Publication: United States NLM ID: 100889084 Publication Model: Print Cited Medium: Internet ISSN: 1557-8593 (Electronic) Linking ISSN: 15209156 NLM ISO Abbreviation: Diabetes Technol Ther Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 31804851 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Efficacy and Safety of Insulin Aspart Biosimilar SAR341402 Versus Originator Insulin Aspart in People with Diabetes Treated for 26 Weeks with Multiple Daily Injections in Combination with Insulin Glargine: A Randomized Open-Label Trial (GEMELLI 1). – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Garg+SK%22">Garg SK</searchLink>; Barbara Davis Center for Diabetes, University of Colorado Anschutz Medical Campus, Aurora, Colorado.<br /><searchLink fieldCode="AU" term="%22Wernicke-Panten+K%22">Wernicke-Panten K</searchLink>; Sanofi-Aventis Deutschland GmbH, Frankfurt, Germany.<br /><searchLink fieldCode="AU" term="%22Wardecki+M%22">Wardecki M</searchLink>; Sanofi, Warszawa, Poland.<br /><searchLink fieldCode="AU" term="%22Kramer+D%22">Kramer D</searchLink>; Sanofi-Aventis Deutschland GmbH, Frankfurt, Germany.<br /><searchLink fieldCode="AU" term="%22Delalande+F%22">Delalande F</searchLink>; Ividata, Paris, France.<br /><searchLink fieldCode="AU" term="%22Franek+E%22">Franek E</searchLink>; Mossakowski Clinical Research Centre, Polish Academy of Sciences, and CSK MSWiA, Warszawa, Poland.<br /><searchLink fieldCode="AU" term="%22Sadeharju+K%22">Sadeharju K</searchLink>; Terveystalo Seinäjoki, Seinäjoki, Finland.<br /><searchLink fieldCode="AU" term="%22Monchamp+T%22">Monchamp T</searchLink>; Endocrinology Services Northwest, Bend, Oregon.<br /><searchLink fieldCode="AU" term="%22Mukherjee+B%22">Mukherjee B</searchLink>; Sanofi, Paris, France.<br /><searchLink fieldCode="AU" term="%22Shah+VN%22">Shah VN</searchLink>; Barbara Davis Center for Diabetes, University of Colorado Anschutz Medical Campus, Aurora, Colorado. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22100889084%22">Diabetes technology & therapeutics</searchLink> [Diabetes Technol Ther] 2020 Feb; Vol. 22 (2), pp. 85-95. – Name: TypePub Label: Publication Type Group: TypPub Data: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; Equivalence Trial – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Mary+Ann+Liebert%2C+Inc%22">Mary Ann Liebert, Inc </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>100889084 <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>1557-8593 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2215209156%22">15209156 </searchLink><i>NLM ISO Abbreviation: </i>Diabetes Technol Ther <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=31804851 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1089/dia.2019.0382 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 85 Titles: – TitleFull: Efficacy and Safety of Insulin Aspart Biosimilar SAR341402 Versus Originator Insulin Aspart in People with Diabetes Treated for 26 Weeks with Multiple Daily Injections in Combination with Insulin Glargine: A Randomized Open-Label Trial (GEMELLI 1). Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Garg SK – PersonEntity: Name: NameFull: Wernicke-Panten K – PersonEntity: Name: NameFull: Wardecki M – PersonEntity: Name: NameFull: Kramer D – PersonEntity: Name: NameFull: Delalande F – PersonEntity: Name: NameFull: Franek E – PersonEntity: Name: NameFull: Sadeharju K – PersonEntity: Name: NameFull: Monchamp T – PersonEntity: Name: NameFull: Mukherjee B – PersonEntity: Name: NameFull: Shah VN IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 02 Text: 2020 Feb Type: published Y: 2020 Identifiers: – Type: issn-electronic Value: 1557-8593 Numbering: – Type: volume Value: 22 – Type: issue Value: 2 Titles: – TitleFull: Diabetes technology & therapeutics Type: main |
| ResultId | 1 |
